Peer Review History

Original SubmissionJune 28, 2020
Decision Letter - Yoshiaki Taniyama, Editor

PONE-D-20-19930

Characteristics, laboratories, and prognoses of severe COVID-19 in the Tokyo metropolitan area: a retrospective case series

PLOS ONE

Dear Dr. Mori,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Both of the reviewers think your paper important, so please response the problems pointed by the review.

Please submit your revised manuscript by Oct 09 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Yoshiaki Taniyama, MD, PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that you have included the phrase “data not shown” in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This is a timely and well done review of the Tokyo experience with COVID-19. It provides some answers but mostly raises some helpful questions regarding the pathophysiology of COVID-19 PNA. Particularly informative was the discussion section where the authors compare the Tokyo experience to that in NYC and Italy. It seems that elevated BMI and hyperlipidemia are pertinent risk factors for COVID-19 PNA.

I would suggest editing of this paper by an individual who speaks English as their first and primary language. There were a number of spelling errors including "Severe" in the very first sentence.

Also, can you explicitly state the criteria for placing a patient in the prone position?

Seeing at the patients were all anticoagulated, were any bleeding complications encountered? eg: epistaxis, hemoptysis. Were INR, PT and PTT monitored? What was the range of these values in those patients who recovered?

Procalcitonin is misspelled- page 14

Ventilator is misspelled table 4.

Overall nice paper. Will add to the medical literature. With these few revisions it should be ready for publication.

Reviewer #2: This manuscript reports characteristics, laboratories, treatment associated cost in ICU of hospitalized COVID-19 patients in the Tokyo metropolitan area. It is a retrospective study with 45 patients, consisting 22 severe cases and 23 mild cases. Descriptive statistics and comparisons between 22 severe cases and 23 mild cases were performed with appropriated statistical methods. Even though the sample size is small, these data may provide valuable information about the observed differences in characteristics, laboratories between severe cases and mild cases. And also reveals the treatment cost in Japan. Below are my questions.

Page 4, 1st paragraph of Patients and admission criteria, should “April 10” be “March 10” as the start time point?

Page 15, Table 4 shows 17( 77.3%) survived in S group. Should 77.3% be discharged rate because the 1st line of page 16 indicates a 86.3% survival rate? Please make those numbers, labels and descriptions be consistent.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

Response to reviewers

We greatly appreciate your kind review of our manuscript entitled “Characteristics, laboratories, and prognosis of severe COVID-19 in the Tokyo metropolitan area: A retrospective case series” and precious comments’ which are of much help to improve our manuscript. We have carefully read the reviewers’ and the academic editor’s comments and made deliberate revisions. The following are our responses (in black) to their comments (in blue) with the revised sentences (in red).

Reviewer #1: This is a timely and well done review of the Tokyo experience with COVID-19. It provides some answers but mostly raises some helpful questions regarding the pathophysiology of COVID-19 PNA. Particularly informative was the discussion section where the authors compare the Tokyo experience to that in NYC and Italy. It seems that elevated BMI and hyperlipidemia are pertinent risk factors for COVID-19 PNA.

Response: We are very grateful for your kind review. We revised our manuscript according to your suggestions and made a response to each comment.

Comment: I would suggest editing of this paper by an individual who speaks English as their first and primary language. There were a number of spelling errors including "Severe" in the very first sentence.

Response: Thank you for your kind suggestion. We have had our manuscript proofread by a doctor, Jean Dominique Morancy, MD, MPH, MBA, who speaks English as a primary language. All the revisions and corrections of grammatical and spelling errors are reflected in the revised manuscript with track changes. Moreover, we expressed our gratitude to the doctor adding the doctor’s name to the acknowledgements section.

Comment: Also, can you explicitly state the criteria for placing a patient in the prone position?

Response: Thank you for your comment. We made a revision regarding the criteria for placing a patient in the prone position as follows.

Page 12-13 (with track changes): added;

Prone Position

The criteria for placing a patient in the prone position are the following. The prone position is considered when (1) the patient’s P/F ratio goes down to below 200; (2) the CT shows severe inflammation and/or consolidation mainly on the dorsal side of the lung. The prone position is considered contraindicated when (1) the patient is unable to tolerate prone position due to hemodynamic instability; (2) the patient has any complications such as internal or external hemorrhages and severe skin damages.

Comment: Seeing at the patients were all anticoagulated, were any bleeding complications encountered? eg: epistaxis, hemoptysis. Were INR, PT and PTT monitored? What was the range of these values in those patients who recovered?

Response: We appreciate your comment. Yes, there are some bleeding complications encountered during the period of this study. The types of complications are hemothorax and chest wall hemorrhage as shown in Table 3. We also described this matter in the last paragraph of ‘Complications’ in the discussion section in page 19-20 (with track changes). Therefore, we did not add any more information to the original text.

In patients with severe COVID-19 and on anticoagulation therapy, especially on heparin, INR, PT and PTT were monitored to avoid hemorrhagic complications due to excessive anticoagulation. However, there was no information regarding the range of these values in those who recovered.

Comment: Procalcitonin is misspelled- page 14. Ventilator is misspelled table 4.

Response: We greatly appreciate your pointing out our mistakes. We had the entire manuscript proofread by Dr. Jean Dominique Morancy, and made corrections of grammatical and spelling errors.

Comment: Overall nice paper. Will add to the medical literature. With these few revisions it should be ready for publication.

Response: Thank you for your kind and encouraging comments. We greatly appreciate them. We have made revisions as much in accordance with the comments as we could. We hope our study will be of much help in the research and clinical fields of COVID-19.

Reviewer #2: This manuscript reports characteristics, laboratories, treatment associated cost in ICU of hospitalized COVID-19 patients in the Tokyo metropolitan area. It is a retrospective study with 45 patients, consisting 22 severe cases and 23 mild cases. Descriptive statistics and comparisons between 22 severe cases and 23 mild cases were performed with appropriated statistical methods. Even though the sample size is small, these data may provide valuable information about the observed differences in characteristics, laboratories between severe cases and mild cases. And also reveals the treatment cost in Japan. Below are my questions.

Response: We greatly appreciate your kind and very valuable comments. We made revisions in accordance with them and hope that our responses meet the suggestions you made.

Comment: Page 4, 1st paragraph of Patients and admission criteria, should “April 10” be “March 10” as the start time point?

Response: Yes, it should be. Thank you for pointing out the important point. We revised this as follows.

Page 4 (with track changes);

Previous: between April 10 and June 2, 2020, a total of 45…

Revised: between March 10th and June 2nd, 2020, a total of 45…

Comment: Page 15, Table 4 shows 17( 77.3%) survived in S group. Should 77.3% be discharged rate because the 1st line of page 16 indicates a 86.3% survival rate? Please make those numbers, labels and descriptions be consistent.

Response: We greatly appreciate your comment. As you suggested, the numbers were not consistent. We made revisions as follows;

Page 15-16 (with track changes), Table 4;

“survived” was changed to “survived and discharged”

Page 17 (with track changes);

Previous: Nineteen Group S patients (86.3%) survived and 17 were discharged.

Revised: Seventeen (77.3%) patients in Group S survived and were discharged.

Page 2; Abstract-Results

Previous: 19 Group S patients (86.4%) survived, 17 (77.3%) were discharged, and 2 are still in treatments. In Group S, 3 died of multiple organ failure.

Revised: in Group S, 19 (86.4%) patients have survived, of which 17 (77.3%) were discharged, and 2 are still in treatments. Three died of multiple organ failure.

Response to the academic editor, regarding journal requirements

2. We note that you have included the phrase “data not shown” in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.

Response: Thank you for your suggestion. The phrase “data not shown” was inappropriate. We added a Supporting Information file to the submission system with a caption and a legend in the manuscript.

Attachments
Attachment
Submitted filename: Response to Reviewers.docx
Decision Letter - Yoshiaki Taniyama, Editor

Characteristics, laboratories, and prognosis of severe COVID-19 in the Tokyo metropolitan area: A retrospective case series

PONE-D-20-19930R1

Dear Dr. Mori,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Yoshiaki Taniyama, MD, PhD

Academic Editor

PLOS ONE

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: (No Response)

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: (No Response)

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: (No Response)

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: (No Response)

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

Formally Accepted
Acceptance Letter - Yoshiaki Taniyama, Editor

PONE-D-20-19930R1

Characteristics, laboratories, and prognosis of severe COVID-19 in the Tokyo metropolitan area: A retrospective case series

Dear Dr. Mori:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr Yoshiaki Taniyama

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .